Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. S. Reddy, M. Khan, N. Methuku, S. Bodi, Aleem (Hyderabad, India). Safety and immunogenicity of hemophilus influenzae type B conjugate vaccine in COPD. Eur Respir J 2008; 32: Suppl. 52, 2017

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) and M. catarrhalis (Mcat) adjuvanted vaccines in adults Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) adjuvanted vaccine in older adults with chronic obstructive pulmonary disease (COPD) Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 Clinical impact of a non-typeable Haemophilus influenzae (NTHi) adjuvanted vaccine in adults with chronic obstructive pulmonary disease (COPD) Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine Source: Eur Respir J 2002; 20: 813-818 Year: 2002 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Pneumococcal vaccination: current and future issues Source: Eur Respir J 2001; 18: 184-195 Year: 2001 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016 Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 673s Year: 2005 Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia Source: Eur Respir J 2004; 24: Suppl. 48, 363s Year: 2004 Microbiological efficacy of combined use of vaccines against S. pneumoniae, H. influenzae type B in patients with a COPD Source: Annual Congress 2011 - Role of infection in exacerbations of COPD Year: 2011 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 HI-164, an oral vaccine to non-typable haemophilus influenzae, reduces antibiotic use, respiratory exacerbations and hospitalisations in patients with COPD Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015 Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Source: Eur Respir J 2004; 23: 363-368 Year: 2004